| 摘要 |
The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIbalpha protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIbalpha protein, and determining complex formation.
|
